Findings from a recent poster abstract highlighted the the amount of supplements patients with alopecia would take in a day compared with the general population.
Data on the efficacy and safety of bimekizumab from 2 phase 3 clinical trials presented at the American Academy of Dermatology Virtual Meeting Experience 2020 showed promising results for the treatment of moderate to severe plaque psoriasis.
To meet the educational needs and plenary requirements normally fulfilled by its in-person event, the Academy announced the AAD Virtual Meeting Experience (VMX), set to take place June 12 to June 14, 2020.